Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acute therapeutic effect of mepolizumab for EGPA-associated neuropathy (prospective observational study)
jRCT1061230097Recruiting
- Sponsor
- GSK
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA), sponsored by GSK. Primary endpoints: Peripheral nerve recovery rate, Electrical diagnosis rate of peripheral nerve recovery and 2 more. Started Feb 2024; status: recruiting.
02
Drugs
mepolizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on jRCT1061230097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061230097.